Follicular Lymphoma

Roche Reports Positive Phase III CELESTIMO Results for Lunsumio-Based Follicular Lymphoma Regimen

Roche announced on September 17, 2026, that the phase III CELESTIMO study evaluating mosunetuzumab (Lunsumio) in combination with lenalidomide met its primary endpoint in people with relapsed or refractory follicular lymphoma (FL) who had received at...